ESOMOWEL 40 is a parenteral Esomeprazole 40 mg formulation positioned for effective gastric-acid suppression in hospital, institutional and physician-led settings. It provides a practical injectable option for patients requiring management of acid-peptic disorders, reflux-related conditions and other clinically appropriate acid-mediated gastrointestinal situations. Its hospital-oriented dosage form gives the brand relevance across gastroenterology, emergency and inpatient practice, strengthening the PCD Pharma Gastro Injectable portfolio.
It is used for acid-related gastrointestinal conditions where injectable proton-pump inhibitor therapy is clinically appropriate.
It can be useful when oral administration is temporarily unsuitable.
Acid suppression begins promptly, but clinical improvement depends on the underlying condition and treatment plan.
Esomeprazole injection should be administered only by qualified healthcare professionals according to the prescribed dose and route. The patient’s clinical indication, duration of treatment and transition to oral therapy should be reviewed where appropriate. Inform the physician about liver disease, long-term acid-suppressive treatment and other medicines. Persistent gastrointestinal symptoms should not be treated indefinitely without reassessment.
Esomeprazole injection is generally well tolerated, although headache, nausea, abdominal discomfort, diarrhea, constipation, dizziness and injection-site reactions may occur. Some patients may experience transient changes in bowel habits or gastrointestinal symptoms. With prolonged treatment, clinically important issues such as magnesium deficiency or vitamin B12 reduction may occur in susceptible patients. Any persistent, severe or unusual symptoms should be evaluated by a physician.
ESOMOWEL 40: Esomeprazole is a proton-pump inhibitor that acts on the H⁺/K⁺-ATPase enzyme system located in gastric parietal cells. It suppresses the final stage of gastric acid secretion, producing potent and sustained reduction in stomach-acid production. Lower acidity helps relieve acid-related irritation and supports healing of acid-mediated gastrointestinal conditions. Injectable administration provides parenteral acid suppression when oral therapy is not appropriate or feasible.
